$453M Settlements in Diabetes Drug Price-Fixing Case Get Tentative Ok from Judge
“A federal judge on Wednesday tentatively approved more than $450 million in settlements with three pharmaceutical giants accused of conspiring to jack up the price of an essential diabetes drug. In a consolidated class action, drug wholesalers claim Bausch Health Companies,” reports Nicholas Iovino in Court House News Service.
“Assertio Therapeutics and their affiliated companies struck anticompetitive deals that caused the price of brand-name diabetes drug Glumetza to spike nearly 800% from $5.72 to more than $51 per tablet in 2015. A jury trial was set to start in early October, but before that could happen motions for settlements with all three pharma giants.”